Ophthalmology

Ophthalmology community continues to rally against efforts to expand the scope of optometrists in multiple states.

According to an American Academy of Ophthalmology news release, Edmond’s priorities during her term include addressing physician and staff shortages and protecting patient safety at a time when nonphysicians are trying to expand their scope of practice into eye surgery.

Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

A look back at some of the biggest stories in ophthalmology in 2023.

Catch up on a few of our top stories and ones you may have missed in 2023

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

Glaukos Corp's iDose TR has received FDA approval for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) following a new drug application (NDA) submission.

Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.

The center includes about 30,000 square feet of space for rapid prototyping of new product designs, enhance manufacturing capabilities, and the expansion of research and development capabilities.

Researchers conducted a large nationwide, population-based, retrospective cohort study to determine if there is an association between COVID-19 infection and vaccination with neuro-ophthalmic adverse events.

Moving toward eliminating drug and chemical safety testing in animals

Physician details her journey from sustaining career-ending injury to insurance advocate.

The Vision Council’s Q3 Provider Insights study shows the sentiments of eye care providers nationwide as they manage practices and patient care.

As ophthalmology continues to advance, there is still room for more ocular cancer understanding and research.

The investigators use mindfulness-based cognitive therapy (MBCT) on patients who have never previously practiced the technique, with the aim of possibly re-training their brains to remove their static-type images.

Michael Rivers, MD, Senior Director of Ophthalmology at ModMed spoke with Modern Retina about their new single-screen initiative and the benefits it could have for saving time and simplifying communication within practices.

The recall is “due to potential safety concerns after FDA investigators found insanitary conditions.”

At first glance, these patients can appear to have normal or near-normal visual acuity levels. However, in reality, many have perceptual visual deficits, which are not typically tested during a standard ophthalmology office evaluation.

This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

Penny Asbell, MD, FACS, spoke with Ophthalmology Times about her poster on results from the ARMOR Study and latest diagnostic and therapeutic advancements in ocular infections at this year's American Academy of Ophthalmology meeting.

Researchers found reduced iron concentration in the clear gel part of the eye of human patients and iron accumulation in the retina of mice.

A mutation-agnostic optogenetic gene therapy is in development using multi-characteristic opsin (MCO) to sensitize the retinal bipolar cells to detect light.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.

Sean Hanlon, CEO of CoFi, spoke with Ophthalmology Times about company updates as well as their integration with CareCredit at this year's American Academy of Ophthalmology meeting.

Rich Small, CEO of Neurotech, spoke with Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.